SCHEMBL9894914

SCHEMBL9894914

CC=C(C(=O)OC)c1ccccc1COc1cccc(OCCNCCO)c1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 7/20 0.48
TSHR P16473 1/20 0.48
POLB P06746 1/20 0.42
CD274 Q9NZQ7 2/20 0.41
MTNR1A P48039 1/20 0.40
MTNR1B P49286 1/20 0.40
KDM4E B2RXH2 2/20 0.40
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
ADRA1D P25100 1/20 0.40
ADRA1A P35348 1/20 0.40
ADRA1B P35368 1/20 0.40
DRD3 P35462 1/20 0.40
NPC1 O15118 1/20 0.39
HTT P42858 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9894913 0.92 HIF1A (0.47) HIF1ATSHRPOLBCD274
SCHEMBL9894911 0.92 HIF1A (0.47) HIF1ATSHRPOLBCD274
SCHEMBL9894915 0.92 HIF1A (0.47) HIF1ATSHRPOLBCD274
SCHEMBL9894943 0.90 HIF1A (0.53) HIF1ACD274MTNR1AMTNR1BKDM4E
SCHEMBL9895242 0.83 HIF1A (0.58) HIF1A
SCHEMBL9895097 0.82 HIF1A (0.69) HIF1AKDM4E
SCHEMBL9894890 0.82 HIF1A (0.67) HIF1ADRD2DRD4ADRA1DADRA1A
SCHEMBL9894938 0.82 HIF1A (0.51) HIF1ACD274KDM4ENPC1RAB9A
SCHEMBL9894945 0.82 HIF1A (0.51) HIF1ACD274KDM4ENPC1RAB9A
SCHEMBL9894940 0.82 HIF1A (0.51) HIF1ACD274KDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8772290-B2 Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same Oscotech Inc. (KR) 2014-07-08 US claimed
EP-2565180-A2 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Oscotec Inc. (KR) 2013-03-06 EP claimed
US-20120149707-A1 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME OSCOTEC INC. (KR) 2012-06-14 US claimed
US-8772290-B2 Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same Oscotech Inc. (KR) 2014-07-08 US disclosed
EP-2565180-A2 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Oscotec Inc. (KR) 2013-03-06 EP disclosed
US-20120149707-A1 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME OSCOTEC INC. (KR) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149707-A1 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME HIF1A, HIF1AN, EGLN3 HIF1A 1/4885TSHR 3700/4885POLB 1442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.